Related Experiment Videos
What are the limits of adjuvanticity?
G Del Giudice1, A Podda, R Rappuoli
1IRIS Research Center, Chiron SpA, Via Fiorentina 1, 53100, Siena, Italy.
Vaccine
|October 6, 2001
Summary
Developing new vaccine adjuvants is crucial for enhancing immunogenicity and reducing reactogenicity. Research focuses on novel adjuvants and alternative delivery routes to improve vaccine efficacy and safety for better public health outcomes.
Area of Science:
- Vaccinology
- Immunology
- Biotechnology
Background:
- Traditional vaccines often have limited immunogenicity due to low antigen purity.
- Modern recombinant antigens, while purer, can exhibit reduced immunogenicity compared to older vaccines.
- Existing vaccine adjuvants have limitations, including reactogenicity and antigen-specific efficacy, with few licensed options available.
Purpose of the Study:
- To explore the challenges and requirements for developing new vaccine adjuvants.
- To evaluate the potential of mucosal adjuvants, such as cholera toxin (CT) and labile enterotoxin (LT) mutants, for alternative vaccine administration routes.
- To address the need for adjuvants that improve immunogenicity and efficacy while minimizing reactogenicity.
Main Methods:
- Review of current vaccine development technologies and adjuvant limitations.
- Analysis of potential mucosal adjuvants and their mechanisms of action.
- Discussion of alternative immunization routes and their impact on adjuvant requirements.
- Evaluation of immunogenicity assessment methods, including antibody titers and cell-mediated immunity.
Main Results:
- Newer, purer antigens may require novel adjuvants to achieve adequate immunogenicity.
- Limited progress in licensing new adjuvants since the introduction of aluminum salts over 70 years ago.
- Cholera toxin (CT) and labile enterotoxin (LT) mutants show promise as mucosal adjuvants, with potential to separate binding and enzymatic effects to manage reactogenicity.
- Current assessment of adjuvanticity via antibody titers may not correlate with protection, highlighting a need for better correlates.
Conclusions:
- Tailoring new adjuvants is essential for developing vaccines with improved immunogenicity and reduced reactogenicity.
- Further research is needed to understand and optimize mucosal adjuvants for alternative delivery routes.
- Developing reliable correlates of protection beyond antibody titers is critical for effective vaccine design.